Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer

NCT00209651 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: Campto, Topotesin
DRUG: TS-1

Sponsor

Hokkaido Gastrointestinal Cancer Study Group

Collaborators

[object Object]